Aquestive Therapeutics, Inc.
General ticker "AQST" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $371.2M (TTM average)
Aquestive Therapeutics, Inc. follows the US Stock Market performance with the rate: 52.1%.
Estimated limits based on current volatility of 2.7%: low 3.16$, high 3.46$
Factors to consider:
- Total employees count: 142 (+5.2%) as of 2024
- US accounted for 69.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Insufficient funds to continue operations, Key executive dependency, Regulatory and compliance, Product liability, Manufacturing disruptions
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.01$, 5.00$]
- 2025-12-31 to 2026-12-31 estimated range: [1.52$, 3.98$]
Financial Metrics affecting the AQST estimates:
- Positive: with PPE of -6.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11.55 <= 0.04
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of -59.31 <= 19.35
- Negative: negative Industry operating income (median)
Short-term AQST quotes
Long-term AQST plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $47.68MM | $50.58MM | $57.56MM |
| Operating Expenses | $89.75MM | $65.69MM | $88.33MM |
| Operating Income | $-42.07MM | $-15.10MM | $-30.77MM |
| Non-Operating Income | $-12.34MM | $7.48MM | $-13.38MM |
| Interest Expense | $12.44MM | $6.56MM | $11.36MM |
| R&D Expense | $17.48MM | $13.10MM | $20.28MM |
| Income(Loss) | $-54.41MM | $-7.62MM | $-44.15MM |
| Taxes | $0.00MM | $0.24MM | $-0.01MM |
| Profit(Loss)* | $-54.41MM | $-7.87MM | $-44.14MM |
| Stockholders Equity | $-118.55MM | $-106.49MM | $-60.16MM |
| Inventory | $5.78MM | $6.77MM | $6.04MM |
| Assets | $57.07MM | $57.42MM | $101.42MM |
| Operating Cash Flow | $-9.82MM | $-6.38MM | $-35.76MM |
| Capital expenditure | $2.52MM | $0.99MM | $0.16MM |
| Investing Cash Flow | $-2.52MM | $-0.99MM | $-0.16MM |
| Financing Cash Flow | $11.59MM | $3.97MM | $83.59MM |
| Earnings Per Share** | $-1.12 | $-0.13 | $-0.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.